Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind placebo-controlled study of IMM-529 plus standard antibiotics in patients with Clostridioides difficile infection
MOH_2017-07-30_000643Phase 2Completed
- Sponsor
- Immuron Limited
- Start
- Mar 2017
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing Standard therapy + placebo with Standard therapy + IMM-529 (2 arms). Primary endpoint: Safety and tolerability of IMM-529 with standard antibiotic therapy. Started Mar 2017; status: completed.
02
Drugs
IMM-529
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on MOH_2017-07-30_000643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-30_000643.